Wieckiewicz Mieszko, Martynowicz Helena, Wieczorek Tomasz, Wojakowska Anna, Sluzalec-Wieckiewicz Katarzyna, Gac Pawel, Poreba Rafal, Mazur Grzegorz, Winocur Efraim, Smardz Joanna
Department of Experimental Dentistry, Wroclaw Medical University, 50-425 Wroclaw, Poland.
Department and Clinic of Internal Medicine, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Brain Sci. 2021 Jan 22;11(2):146. doi: 10.3390/brainsci11020146.
Sleep bruxism (SB) management aims to reduce the number and magnitude of bruxism episodes per hour of a patient's sleep and, therefore, reduce the potentially negative clinical consequences. Opipramol belongs to the group of tricyclic antidepressants (TCAs) and is considered as an atypical TCA, as it acts primarily as a sigma receptor agonist. This study aimed to preliminarily determine the effectiveness of opipramol in the management of severe SB.
A total of 19 otherwise healthy participants with severe SB diagnosed during stage I video polysomnography (vPSG) were subjected to an 8-week pharmacotherapy trial with a 100 mg bedtime daily dose of opipramol and were then analyzed by control stage II vPSG.
The participants included 14 females and 5 males, aged 20-47 years (mean ± standard deviation: 32.32 ± 8.12). A comparison of stage I and II vPSG recordings showed a decrease in all the studied SB parameters in 78.85% of participants. Only in a small group of participants (15.53%) was a non-significant increase of SB parameters observed.
A single 100 mg dose of opipramol at bedtime seems to positively affect the reduction of SB in otherwise healthy individuals diagnosed with severe SB. However, the subject requires further research on a larger population including a control group.
睡眠磨牙症（SB）的治疗旨在减少患者每小时睡眠中磨牙发作的次数和强度，从而减少潜在的负面临床后果。奥匹哌醇属于三环类抗抑郁药（TCA），被认为是一种非典型的三环类抗抑郁药，因为它主要作为西格玛受体激动剂起作用。本研究旨在初步确定奥匹哌醇治疗重度睡眠磨牙症的有效性。
共有19名在第一阶段视频多导睡眠图（vPSG）检查中被诊断为患有重度睡眠磨牙症的健康参与者，接受为期8周的药物治疗试验，每天睡前服用100毫克奥匹哌醇，然后通过第二阶段对照vPSG进行分析。
参与者包括14名女性和5名男性，年龄在20至47岁之间（平均±标准差：32.32±8.12）。第一阶段和第二阶段vPSG记录的比较显示，78.85%的参与者所有研究的睡眠磨牙症参数均有所下降。只有一小部分参与者（15.53%）的睡眠磨牙症参数有不显著的增加。
对于被诊断患有重度睡眠磨牙症的健康个体，每晚睡前单次服用100毫克奥匹哌醇似乎对减少睡眠磨牙症有积极作用。然而，该课题需要在包括对照组的更大人群中进行进一步研究。
